Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our entries into China and the United States provide the necessary market dynamics for a healthy business model with significant growth |
| We are entering this year with a solid foundation and with the clear path to become the leading global company in breast aesthetics and reconstruction |
| Our interactions with the agency on Motiva remain very positive and we continue to make progress |
| Our global market checks suggest that we will have continued improvement throughout 2024 |
| With these actions, we expect to achieve positive adjusted EBITDA in 2024 and positive cash flow in 2025 |
| So we do expect this to eventually be an important contributor over the next few years to our growth and definitely it has the highest ASPs in the world and highest gross margins for any market for tissue expanders |
| We are well-positioned for multiyear growth and poised to take global market leadership in an industry that has not brought any meaningful innovation to market in more than two decades |
| Moreover, the testimonials from women reinforced the value proposition based on convenience, quick recovery and excellent aesthetic outcomes |
| And, yes, and I think this data will show as – it has shown in the past, that we have an amazing technology with superior safety results |
| Juan José Chacón Quirós Look, just like everyone we are super excited with Mia, particularly, because we see the amazing results and the differentiated experience |
| 2024 is also the year in which we will achieve the necessary scale to become EBITDA positive, with a clear path to cash flow positive |
| By the time we go to market, I think that we’ll be in a good position to take over demand, and the fact that if we might go the market with one less competitor, of course, adds up to the opportunity |
| With the cash we have on hand and the amendment to our credit facility, we are in an excellent position to fund our growth initiatives while meeting our profitability targets |
| This is a distinct advantage to Flora, as all other commercially available breast tissue expanders include magnets |
| In markets like South Korea, Japan, Thailand, Vietnam, Singapore, Hong Kong and Taiwan, we hold the number one market share position, and China should match this success over time |
| It is still early in the launch of Mia, but we are seeing proof points that we’re creating and capturing new consumer demand in this new category in breast aesthetics |
| While our second half results reflected lower demand for breast procedures globally, our markets are stabilizing and we are seeing improving demand, including from our distributors |
| China is the second largest market for breast augmentation and has among the highest ASPs in the world |
| So we are feeling pretty good about where we are in terms of getting ready for being commercial with their entire portfolio in the U.S |
| This guidance does not include the launch of Motiva Implants in the United States, which would significantly improve both our revenue and growth |
| We are confident in our ability to do this early next year and have model or cash spent accordingly |
| Mia is gaining appeal with a new consumer |
| And that’s why we’re so confident on the growth of Mia |
| With the approval of our implants in China and our pending approval in the United States, we are becoming a true global player in our industry |
| So we expect this to continue taking place at different speeds in these regions, but when we think about guidance for this year, I think what you should think of is conditions improving throughout this year |
| The fact that these women are just going back to their daily lives minus the exercise the same day is just an amazing thing to see |
| was actually hit quite strongly by this global slowdown in aesthetics, but from different indicators, we know the situation is improving |
| So, the network of Mia certified centers is increasing and what we are seeing is in the first group of clinics that launched in second half of last year we were seeing increasing demand every month |
| Flora launch? I think Sientra had a relatively strong recon franchise |
| And yeah, of course, as we look into the expansion of Flora, this provides for an opportunity for us to be able to bring our fully differentiated tissue expander to U.S |
| Statement |
|---|
| Total revenue for the fourth quarter was $31.6 million, a decline of 28% from the year ago period |
| A gross profit in the fourth quarter was negatively impacted by an obsolescence charge, without which gross margins would have been approximately 66% |
| But, I think that probably the slowdown in aesthetics overall probably exacerbated the demise of that company |
| A gross margin was also impacted by higher overhead and labor costs |
| R&D expenses for the fourth quarter declined approximately $700,000 from the same quarter year ago to $5.8 million and were down $1.3 million, sequentially |
| So it’s not surprising in that situation the smallest of companies was not able to survive |
| SG&A declined $3.1 million sequentially from the third quarter |
| But then over the course of year, the overall expense base is going to be significantly lower than where it was last year |
| Since we launched Motiva 14 years ago, we have been in the most price-sensitive markets with low-ASPs and gross margins |
| But, overall, I think that just like any other slowdown that we have seen in the past, eventually it goes back |
| Establishment Labs was founded on bringing differentiated technology to an industry that has seen little innovation for decades |
| approval is really going to step down our spending here too dramatically |
| The net loss from operations for the fourth quarter was $22.1 million compared to a net loss of $13.2 million in the same period in 2022 |
| I think when we lowered the guidance coming out of the third quarter for 2023, we talked about China being roughly $10 million of the reduction in 2023 |
| Things are not fully back to normal |
| should be relatively short |
| Juan José Chacón Quirós Yeah, so if you want to think about it by regions, I think that probably Latin America and, most importantly, Brazil have not recovered as quickly as other markets |
| When we think about the assumptions underpinning your guidance, in early January, you talked about how markets haven’t necessarily recovered, but that previous weakness looks to have stabilized |
| The approval came a little bit later than expected, but you were previously expecting a contribution in the low-teens in fourth quarter |
Please consider a small donation if you think this website provides you with relevant information